Copyright
©The Author(s) 2015.
World J Respirol. Jul 28, 2015; 5(2): 112-125
Published online Jul 28, 2015. doi: 10.5320/wjr.v5.i2.112
Published online Jul 28, 2015. doi: 10.5320/wjr.v5.i2.112
Table 1 An overview of the futures of the three adaptive servo-ventilation devices
| Manufacturer | ResMed | Philips-Respironics | Weinmann |
| Current version | S9 VPAP Adapt, AutoSet CS-A | BiPAP autoSV Advanced System One | Prisma LINE CR |
| EPAP (default) | 4-15 cmH2O auto | 4-15 cmH2O auto | 4-20 cmH2O auto |
| (min EPAP) | 4-15 cmH2O | 4-25 cmH2O | 4-20 cmH2O |
| (max EPAP) | min EPAP-15 cmH2O | min EPAP-25 cmH2O | min EPAP-20 cmH2O |
| IPAP | Max 30 cmH2O | Max 25 cmH2O | Max 30 cmH2O |
| PS | 0 to 30-prevailing EPAP | 0 to 25-prevailing EPAP | 0 to 30-prevailing EPAP |
| Calculation | The recent 3-min average minute volume | The recent 4-min average peak flow | The average of the minute volume in the recent 2-min and an earlier interval |
| Target for PS | 90% of the average minute volume | 90%-95% of the average peak flow (without SDB) | Relative minute volume of the current breath to the average |
| 60% percentile of peak flow (with SDB) | |||
| Approximate the minute volume to the target | Approximate the peak inspiratory flow to the target | Stabilize the relative minute volume | |
| Backup rate | Auto (cannot be established manually) | Auto (default) or fixed rate | Auto (default) or fixed rate |
Table 2 Clinical trials assessing the effects of adaptive-servo ventilation on cardiac function in heart failure patients with central sleep apnea
| Ref. | Study design | n | Duration (mo) | Baseline | Device usage (h) | Changes | ||
| AHI | EF | AHI | EF | |||||
| Pepperell et al[36] | RCT | |||||||
| Subtherapeutic | 15 | 1 | 17.7 | 35.7 | 3.9 | -3 | 0.5 | |
| Therapeutic | 15 | 21.9 | 36.5 | 5.0 | -16.5 | 1.8 | ||
| Philippe et al[3] | RCT | |||||||
| CPAP | 13 | 6 | 40.5 | 30.0 | 4.2 | -20 | -2 | |
| ASV | 12 | 47.0 | 29.0 | 5.8 | -45 | 7 | ||
| Fietze et al[37] | RCT | |||||||
| Bi-level PAP | 15 | 1.5 | 34.9 | 25.5 | 4.81 | -18.5 | 5.6 | |
| ASV | 15 | 31.7 | 24.6 | -20.5 | 1.9 | |||
| 1Kasai et al[4] | RCT | |||||||
| CPAP-mode | 11 | 3 | 23.02 | 33.0 | 3.3 | 0.1 | -1 | |
| ASV-mode | 12 | 25.02 | 32.0 | 4.7 | -23 | 5.8 | ||
Table 3 Clinical trials assessing the effects of adaptive-servo ventilation on cardiac function in heart failure patients with central sleep apnea and coexisting obstructive sleep apnea
| Ref. | Study design | n | Duration (mo) | Baseline | Device usage (h) | Changes | ||
| AHI | EF | AHI | EF | |||||
| Kasai et al[40] | RCT | |||||||
| CPAP | 15 | 3 | 38.6 | 36 | 4.4 | -23.2 | 1.9 | |
| f-ASV | 16 | 36.3 | 35.7 | 5.25 | -35.4 | 9.1 | ||
| Randerath et al[41] | RCT | |||||||
| CPAP | 34 | 12 | 41 | 43 | 4.3 | -24.0 | 4.9 | |
| f-ASV | 36 | 47 | 47 | 5.2 | -36.0 | -1.9 | ||
| Yoshihisa et al[42] | RCT | |||||||
| Control | 18 | 6 | 36 | 54 | - | -8.2 | -2.0 | |
| v-ASV | 18 | 37 | 56.1 | 5.6 | -30.2 | 5.1 | ||
| Birner et al[43] | RCT | |||||||
| Control | 35 | 3 | 43 | 29 | - | 0 | 3.0 | |
| f-ASV | 37 | 52 | 30 | 4.2 | -41.0 | 1.0 | ||
Table 4 Summary of recommendations for the use of adaptive-servo ventilation in various settings
| Settings | Indication | Improvement other than AHI | Supporting evidence |
| With SDB | |||
| HF | After optimization of HF, with CSA not suppressed by CPAP | Daytime sleepiness | RCTs (vs CPAP)[3,4,40,41,43] |
| LVEF | RCTs (vs control)[36,42] | ||
| BNP | RCT (vs Bi-level PAP)[37] | ||
| Event-free survival | |||
| Treatment-emergent CSA | With HF | Same as HF | |
| Without HF | Sleep architecture | Retrospective studies (pre-post study, vs CPAP)[64,65] | |
| Adherence of PAP | |||
| Idiopathic CSA | With symptoms | Daytime alertness and mood | Case series (pre-post study, vs CPAP or oxygen)[5] |
| Opioid-induced CSA | Benefit unknown | ||
| Stroke-related CSA | Post-acute phase | Daytime sleepiness | A single-center retrospective study (pre-post study)[86] |
| Without SDB | |||
| HF | Regardless of the presence or absence of SDB | LVEF | A multi-center retrospective study (pre-post study)[91] |
| NYHA class | |||
| Acute cardiogenic pulmonary edema | With elevated filling pressure | Dyspnea | An observational study (vs supplemental oxygen alone)[12] |
| High blood pressure | |||
| Atrial fibrillation | During PVI | Procedural time | On-off study[93] |
- Citation: Tomita Y, Kasai T. Effectiveness of adaptive servo-ventilation. World J Respirol 2015; 5(2): 112-125
- URL: https://www.wjgnet.com/2218-6255/full/v5/i2/112.htm
- DOI: https://dx.doi.org/10.5320/wjr.v5.i2.112
